High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia (vol 135, pg 866, 2020)

被引：0
|
作者：
Al-Sawaf, O.
Lilienweiss, E.
Bahlo, J.
机构：
来源：
BLOOD | 2022年 / 139卷 / 25期
关键词：
D O I：
10.1182/blood.2022015745
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3669 / 3669
页数：1
相关论文
共 50 条
  • [1] High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Lilienweiss, Esther
    Bahlo, Jasmin
    Robrecht, Sandra
    Fink, Anna-Maria
    Patz, Michaela
    Tandon, Maneesh
    Jiang, Yanwen
    Schary, William
    Ritgen, Matthias
    Tausch, Eugen
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Fischer, Kirsten
    Hallek, Michael
    Kreuzer, Karl-Anton
    BLOOD, 2020, 135 (11) : 866 - 870
  • [2] Venetoclax and obinutuzumab in chronic lymphocytic leukemia (vol 129, pg 2702, 2017)
    Fischer, K.
    Al-Sawaf, O.
    Fink, A-M
    BLOOD, 2017, 130 (02) : 232 - 232
  • [3] ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Fischer, Kirsten
    Robrecht, Sandra
    Zhang, Can
    Ahn, Inhye E.
    Lura, Michele Porro
    Sinai, Wendy
    Chyla, Brenda
    Sail, Kavita
    Pesko, John
    Pai, Madhavi
    Komlosi, Viktor
    Hallek, Michael
    Brown, Jennifer R.
    Al-Sawaf, Othman
    BLOOD, 2021, 138
  • [4] The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab
    Guinan, Kimberly
    Mathurin, Karine
    Lachaine, Jean
    Roc, Nancy Paul
    Bull, Sarah-Jane
    Tankala, Dipti
    Barakat, Stephane
    Manzoor, Beenish S.
    Hillis, Christopher
    Banerji, Versha
    CANCERS, 2024, 16 (18)
  • [5] MAJIC: a phase III trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Ryan, Christine E.
    Davids, Matthew S.
    Hermann, Richard
    Shahkarami, Mina
    Biondo, Juliana
    Abhyankar, Sarang
    Alhasani, Hasan
    Sharman, Jeff P.
    Mato, Anthony R.
    Roeker, Lindsey E.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3689 - 3699
  • [6] Complex karyotype in patients with chronic lymphocytic leukemia.
    Yañez, L
    Cuadrado, MA
    Insunza, A
    Mesones, BG
    Bermudez, A
    Conde, E
    Bureo, E
    Iriondo, A
    BLOOD, 2005, 106 (11) : 328B - 328B
  • [7] COMPLEX KARYOTYPE AS A PROGNOSTIC MARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS DURING TREATMENT WITH CHEMOIMMUNOTHERAPY BTKI AND VENETOCLAX
    Tocci, D.
    Peccia, K.
    Crupi, R.
    Ciofini, S.
    Bocchia, M.
    Gozzetti, A.
    HAEMATOLOGICA, 2024, 109 : 95 - 95
  • [8] THE BUDGET IMPACT OF VENETOCLAX PLUS OBINUTUZUMAB FOR FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN SAUDI ARABIA
    Alrajhi, A. M.
    Al-Abdulkarim, H.
    Khan, M.
    Alkhudair, N.
    Alshehri, H.
    Fasseeh, A.
    Aziz, A. Abd-El
    Elezbawy, B.
    Abaza, S.
    Ahmed, Y.
    Sheriba, A. N.
    Semida, A.
    Alnajjar, F.
    VALUE IN HEALTH, 2024, 27 (12)
  • [9] The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab
    Guinan, Kimberly
    Lachaine, Jean
    Roc, Nancy Paul
    Bull, Sarah-Jane
    Tankala, Dipti
    Barakat, Stephane
    Hillis, Christopher M.
    Banerji, Versha
    BLOOD, 2022, 140 : 2157 - 2158
  • [10] Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Herling, Carmen Diana
    Holtick, Udo
    Scheid, Christoph
    Cramer, Paula
    Sasse, Stephanie
    von Tresckow, Bastian
    Tuchscherer, Armin
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    Frenzel, Lukas P.
    HAEMATOLOGICA, 2019, 104 (05) : E224 - E226
12345